US5017577A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods for treating viral infection
Assignee: SmithKline Beecham Corp
•
Filing: 1989-07-19
•
Granted: 1991-05-21
•
Expires: 2009-07-19
Abstract
Abstract The present invention relates to certain novel 8-phenylxanthines substituted in the 3 or 4 position of the phenyl group by an alkenylene, alkenyleneoxy, alkynylene or alkynyleneoxy bearing a terminal acidic grouping, and to their use in human and veterinary therapy, particularly for conditions associated with the cell surface effects of adenosine and in antiviral, especially antiretroviral, chemotherapy.
Inventors
- 👤 Susan M. Daluge
- 👤 Harry J. Leighton
- 👤 Sandra N. Lehrman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 07:24
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/519; A61K31/52
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
189 words
A method for the treatment of a virus infection in virus infected animal which comprises administering to said animal a therapeutically effective amount of a compound of formula I ##STR15## wherein: X 1 and X 2 are the same or different and are hydrogen, C 1-6 alkyl, C 2-6 alkenyl or C 7-12 aralkyl optionally substituted in the aryl ring by at least one substituent selected from C 1-6 alkyl, C 1-6 alkoxy, hydroxy, halo, nitro, amino, azido and cyano, provided that both X 1 and X 2 are not hydrogen; one of X 3 and X 4 is hydrogen, C 1-6 alkyl, trifluoromethyl, C 1-6 alkoxy, haio, nitro, amino, C 1-6 alkoxycarbonyl or carboxy and the other is a group --Y--Z where Y is C 2-6 alkenylene, or C 3-6 alkenyleneoxy, C 2-6 alkynylene or C 3-6 alkynyleneoxy and Z is carboxy, sulphonyl or phosphonyl or a C 1-9 alkyl ester, a C 7-12 aralkyl ester or a C 6-12 aryl ester thereof, or is 5-tetrazolyl; and X, and X are the same or different and are oxygen or sulphur; or a pharmaceutically acceptable salt or solvate thereof.
Claim 2
Independent Claim
189 words
A method for the treatment of a virus infection in virus infected animal which comprises administering to said animal a therapeutically effective amount of a compound of formula I ##STR15## wherein: X 1 and X 2 are the same or different and are hydrogen, C 1-6 alkyl, C 2-6 alkenyl or C 7-12 aralkyl optionally substituted in the aryl ring by at least one substituent selected from C 1-6 alkyl, C 1-6 alkoxy, hydroxy, halo, nitro, amino, azido and cyano, provided that both X 1 and X 2 are not hydrogen; one of X 3 and X 4 is hydrogen, C 1-6 alkyl, trifluoromethyl, C 1-6 alkoxy, haio, nitro, amino, C 1-6 alkoxycarbonyl or carboxy and the other is a group --Y--Z where Y is C 2-6 alkenylene, or C 3-6 alkenyleneoxy, C 2-6 alkynylene or C 3-6 alkynyleneoxy and Z is carboxy, sulphonyl or phosphonyl or a C 1-9 alkyl ester, a C 7-12 aralkyl ester or a C 6-12 aryl ester thereof, or is 5-tetrazolyl; and X, and X are the same or different and are oxygen or sulphur; or a pharmaceutically acceptable salt or solvate thereof.
Claim 3
Dependent Claim
12 words
A method according to claim 1 wherein said animal is a mammal.
Claim 4
Dependent Claim
13 words
A method according to claim 2 wherein said mammal is a human being.
Claim 5
Dependent Claim
14 words
A method according to claim 3 wherein said virus infection is a retrovirus infection.
Claim 6
Dependent Claim
14 words
A method according to claim 4 wherein said retrovirus infection is an AIDV infection.
Claim 7
Dependent Claim
14 words
A method according to claim 4 wherein said retrovirus infection is an HTLV-I infection.
Claim 8
Dependent Claim
29 words
A method according to claim 1 wherein said compound is selected from (E)-4-(1,3-dibutyl-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid, (E)-4-(1,3-dibutyl-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid, (E)-4-(1-benzyl-1,2,3,6-tetrahydro-2,6-dioxo-3-propyl-9H-purin-8-yl)cinnamic acid and (E)-4-(3-benzyl-1,2,3,6-tetrahydro-2,6-dioxo-1-propyl-9H-purin-8-yl)cinnamic acid, or a pharmaceutically acceptable salt or solvate thereof.
Claim 9
Dependent Claim
17 words
A method according to claim 5 wherein said compound is selected from the compounds of claim 7.
Claim 10
Dependent Claim
13 words
The method of claim 1 in which the compound is (E)-4-(1,3-dibenzyl-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl) cinnamic acid.
Claim 11
Dependent Claim
13 words
The method of claim 4 in which the compound is (E)-4-(1,3-dibenzyl-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl) cinnamic acid.
Claim 12
Dependent Claim
13 words
The method of claim 5 in which the compound is (E)-4-(1,3-dibenzyl-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl) cinnamic acid.
References Cited (Backward Citations)
US4593095A
Cited
US4612315A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-05-20 | 1994-11-19 | 1995-05-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-05-20 | 1998-11-19 | 1999-05-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-05-20 | 2002-11-19 | 2003-05-21 | $7700.00 | Window Closed / Lapsed |